Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ENRD +14.3%, FLXS +11.5%, DUOT +6.6%, PONY +3.4%, HD +1.8%, NKLR +1.7%, AS +0.7%
Other news:
- AMLX +21.3% (topline results from phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia)
- ENRD +14.4% (partners with Tesla (TSLA) on planned 500-Semi deployment)
- KURA +7% (CEO insider purchase)
- HAE +6.3% (entered into a supply agreement with CSL Plasma)
- BLSM +4.6% (FDA fast track designation for BH-30643, a macrocyclic OMNI-EGFR inhibitor for the treatment of advanced EGFR C797S-positive NSCLC)
- PSN +2.7% (awarded a $664.8 mln Army contract)
- GHI +2.2% (sells Vantage at Loveland)
- BFLY +2.2% (Director insider purchase)
- CNL +1.9% (completes Guayabales access road; adit construction on track for Q4 2026, Trap underground drilling set for Q1 2027)
- TRGP +1.8% (signs 20-year ExxonMobil midstream deals, adds three Permian Delaware gas plants)
- DT +1.3% (prices $1.25 bln 0.00% exchangeable senior notes due 2031)
- DLX +1.1% (names President of Merchant Services division)